Structure Therapeutics Quarterly Income Statements Chart
Quarterly
|
Annual
Structure Therapeutics Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| operating expenses: | |||||||||||
| research and development | 54,710,000 | 42,867,000 | 33,487,000 | 32,598,000 | 22,050,000 | 20,679,000 | 20,042,000 | 17,515,000 | 19,411,000 | 13,135,000 | |
| general and administrative | 15,741,000 | 13,444,000 | 13,574,000 | 13,238,000 | 11,266,000 | 11,336,000 | 10,952,000 | 8,630,000 | 6,576,000 | 6,514,000 | |
| total operating expenses | 70,451,000 | 56,311,000 | 47,061,000 | 45,836,000 | 33,316,000 | 32,015,000 | 30,994,000 | 26,145,000 | 25,987,000 | 19,649,000 | |
| income from operations | -70,451,000 | -56,311,000 | -47,061,000 | -45,836,000 | -33,316,000 | -32,015,000 | -30,994,000 | -26,145,000 | -25,987,000 | -19,649,000 | |
| yoy | 111.46% | 75.89% | 51.84% | 75.31% | 28.20% | 62.93% | |||||
| qoq | 25.11% | 19.66% | 2.67% | 37.58% | 4.06% | 3.29% | 18.55% | 0.61% | 32.26% | ||
| operating margin % | |||||||||||
| interest and other income | 8,929,000 | 9,576,000 | 10,718,000 | 11,951,000 | 7,335,000 | 6,008,000 | 6,179,000 | 2,688,000 | 2,825,000 | 1,699,000 | |
| income before benefit from income taxes | -61,522,000 | -46,735,000 | -36,343,000 | -33,885,000 | -25,981,000 | -26,007,000 | -24,815,000 | -23,457,000 | -23,162,000 | -17,950,000 | |
| benefit from income taxes | 139,000 | 98,000 | 136,000 | 92,000 | 53,000 | 29,000 | -312,000 | 405,000 | 118,000 | 25,000 | |
| net income attributable to ordinary shareholders | -61,661,000 | -46,833,000 | -36,479,000 | -33,977,000 | -26,034,000 | -26,036,000 | -24,503,000 | -23,862,000 | -23,280,000 | -17,975,000 | |
| net income per share | -0.36 | -0.27 | -0.22 | -0.2 | -0.18 | -0.19 | -0.16 | -0.21 | -0.2 | -0.25 | |
| weighted-average ordinary shares used in computing net income per share attributable to ordinary shareholders, basic and diluted | 172,647 | 172,051 | 157,922 | 171,630 | 148,239 | 139,710 | 110,198 | 114,948 | 114,759 | 71,655 | |
| other comprehensive loss: | |||||||||||
| unrealized loss on investments | -453 | -99 | -397 | -537 | |||||||
| total other comprehensive loss | -453 | -99 | -397 | -50 | 80 | -537 | |||||
| comprehensive loss | -62,114 | -46,932 | -38,404 | -30,651 | -26,431 | -26,647 | -23,672 | -23,782 | -23,817 | -17,718 | |
| | |||||||||||
| other comprehensive gain: | |||||||||||
| unrealized gain on investments | -1,925 | 3,326 | -611 | 831 | 80 | 257 | |||||
| total other comprehensive gain | -1,925 | 3,326 | 257 | ||||||||
| total other comprehensive income | -611 | ||||||||||
| net income | -24,503,000 | -23,862,000 | -23,280,000 | ||||||||
| yoy | |||||||||||
| qoq | 2.69% | 2.50% | |||||||||
| net income margin % | |||||||||||
| less: accretion of redeemable convertible preferred shares to their redemption value |
We provide you with 20 years income statements for Structure Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Structure Therapeutics stock. Explore the full financial landscape of Structure Therapeutics stock with our expertly curated income statements.
The information provided in this report about Structure Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.